Regulatory Affairs
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Navigate global pharma regulatory affairs. Get expert insights on FDA, EMA, and global compliance for drug approvals, market access, and R&D strategy.
Showing 1–12 of 22 articles
Quick answer
NovaPharmaNews Regulatory Affairs hub for FDA covers 22 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
DIA 2024: What to Expect in Regulatory Affairs
THMA CPE Circle Highlights Key Trends in Pharma
Clene Receives FDA Green Light for CNM-Au8 Accelerated Approval Pathway in ALS Treatment
Aquestive Therapeutics Faces Securities Fraud Lawsuit Despite Anaphylm FDA Review Progress
Avicanna Welcomes U.S. Cannabis Rescheduling Decision, Advances Medical Cannabis R&D Strategy
C-Ray Therapeutics Receives FDA Acceptance for Copper-64 Drug Master File, Advancing Radiopharmaceutical Development
FDA Generic Drug User Fee Amendments (GDUFA) Program Updates Fee Structure and Payment Methods for 2024
FDA Proposes OMUFA User Fee Program for Over-the-Counter Monograph Drugs to Supplement Congressional Funding
FDA Begins Preparation for GDUFA IV Reauthorization: Generic Drug User Fee Program 2028-2032
FDA Encourages Testosterone Therapy Expansion for Low Libido in Men with Hypogonadism
FDA Achieves Year 1 Goals in Reducing Animal Testing for Drug Development Through Alternative Methods
CMS and FDA Launch RAPID Coverage Pathway for Breakthrough Medical Devices Under Medicare
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.